Difference between revisions of "Part:BBa K4165192"

(Usage and Biology)
 
(One intermediate revision by the same user not shown)
Line 6: Line 6:
  
 
===Usage and Biology===
 
===Usage and Biology===
Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acid 32 to 42 of the fibril.
+
Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acid 29 to 42 of the fibril.
  
 
===<span class='h3bb'>Sequence and Features</span>===
 
===<span class='h3bb'>Sequence and Features</span>===
 
<partinfo>BBa_K4165192 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4165192 SequenceAndFeatures</partinfo>
 +
  
 
=== Dry Lab Characterization ===
 
=== Dry Lab Characterization ===

Latest revision as of 19:36, 11 October 2022


Amyloid beta peptide 12 (Aβ 29-42)

This part encodes a part of the Amyloid 𝛽 fragment (29-42) which has the ability to bind to A𝛽 plaques inside the brain.

Usage and Biology

Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acid 29 to 42 of the fibril.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Dry Lab Characterization

Modeling

The peptide was modeled by several software (Alphafold-Apptest-Pepfold) and the best model from Apptest scored 1 out of 6 according to our Quality assessment code.

                              Figure 1.: Amyloid-beta (29-42) top model visualized by Pymol.

References

Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.